From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?

From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?

In 2018, the Food and Drug Administration (FDA) approval of anti-calcitonin gene-related peptide (CGRP) therapies for the treatment of migraine represented a milestone for the management of the disease in adults. On the contrary, the novelties in the field of pediatric migraine are inserted in a dif...

Full description

Bibliographic Details
Main Authors: Laura Papetti, Samuela Tarantino, Fabiana Ursitti, Romina Moavero, Martina Checchi Proietti, Giorgia Sforza, Gabriele Monte, Michela Ada Noris Ferilli, Martina Balestri, Federico Vigevano, Massimiliano Valeriani
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Neurology
Subjects:
migraine
headache
children
treatment
management
diagnosis
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.935803/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.935803/full

Similar Items